Please use this identifier to cite or link to this item:
Title: Granzyme B PET Imaging of Combined Chemotherapy and Immune Checkpoint Inhibitor Therapy in Colon Cancer
Authors: Goggi, Julian L.
Hartimath, Siddesh, V
Xuan, Tan Yun
Khanapur, Shivashankar
Jieu, Beverly
Chin, Hui Xian
Ramasamy, Boominathan
Cheng, Peter
Rong, Tang Jun
Fong, Yong Fui
Yuen, Tsz Ying
Msallam, Rasha 
Chacko, Ann-Marie 
Renia, Laurent
Johannes, Charles
Hwang, You Yi
Robins, Edward G. 
Keywords: Checkpoint inhibitors
Granzyme B
Issue Date: 12-Mar-2021
Publisher: Springer Science and Business Media Deutschland GmbH
Citation: Goggi, Julian L., Hartimath, Siddesh, V, Xuan, Tan Yun, Khanapur, Shivashankar, Jieu, Beverly, Chin, Hui Xian, Ramasamy, Boominathan, Cheng, Peter, Rong, Tang Jun, Fong, Yong Fui, Yuen, Tsz Ying, Msallam, Rasha, Chacko, Ann-Marie, Renia, Laurent, Johannes, Charles, Hwang, You Yi, Robins, Edward G. (2021-03-12). Granzyme B PET Imaging of Combined Chemotherapy and Immune Checkpoint Inhibitor Therapy in Colon Cancer. Molecular Imaging and Biology 23 (5) : 714-723. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: Purpose: Chemotherapeutic adjuvants, such as oxaliplatin (OXA) and 5-fluorouracil (5-FU), that enhance the immune system, are being assessed as strategies to improve durable response rates when used in combination with immune checkpoint inhibitor (ICI) monotherapy in cancer patients. In this study, we explored granzyme B (GZB), released by tumor-associated immune cells, as a PET imaging-based stratification marker for successful combination therapy using a fluorine-18 (18F)-labelled GZB peptide ([18F]AlF-mNOTA-GZP). Methods: Using the immunocompetent CT26 syngeneic mouse model of colon cancer, we assessed the potential for [18F]AlF-mNOTA-GZP to stratify OXA/5-FU and ICI combination therapy response via GZB PET. In vivo tumor uptake of [18F]AlF-mNOTA-GZP in different treatment arms was quantified by PET, and linked to differences in tumor-associated immune cell populations defined by using multicolour flow cytometry. Results: [18F]AlF-mNOTA-GZP tumor uptake was able to clearly differentiate treatment responders from non-responders when stratified based on changes in tumor volume. Furthermore, [18F]AlF-mNOTA-GZP showed positive associations with changes in tumor-associated lymphocytes expressing GZB, namely GZB+ CD8+ T cells and GZB+ NK+ cells. Conclusions: [18F]AlF-mNOTA-GZP tumor uptake, driven by changes in immune cell populations expressing GZB, is able to stratify tumor response to chemotherapeutics combined with ICIs. Our results show that, while the immunomodulatory mode of action of the chemotherapies may be different, the ultimate mechanism of tumor lysis through release of Granzyme B is an accurate biomarker for treatment response. © 2021, The Author(s).
Source Title: Molecular Imaging and Biology
ISSN: 1536-1632
DOI: 10.1007/s11307-021-01596-y
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1007_s11307-021-01596-y.pdf2.59 MBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons